| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6800620 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8138195 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8637533 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US6949535 | GILEAD SCIENCES INC | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| US8492389 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(3 years ago) | |
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(1 year, 3 months from now) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(8 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 17 days from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(1 year, 17 days from now) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(1 year, 2 months from now) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(5 years from now) | |
Zydelig is owned by Gilead Sciences Inc.
Zydelig contains Idelalisib.
Zydelig has a total of 13 drug patents out of which 5 drug patents have expired.
Expired drug patents of Zydelig are:
- US6800620
- US8138195
- US8637533
- US6949535
- US8492389
Zydelig was authorised for market use on 23 July, 2014.
Zydelig is available in tablet;oral dosage forms.
Zydelig can be used as a method of disrupting leukocyte function, including as an inhibitor of pi3kdelta kinase, for the treatment of patients with relapsed chronic lymphocytic leukemia, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll), for the treatment of patients with cll, fl, or sll, inhibition on pi3k kinase.
Drug patent challenges can be filed against Zydelig from 23 July, 2018.
The generics of Zydelig are possible to be released after 02 September, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll); A method o...
Dosage: TABLET;ORAL
ZYDELIG family patents
